Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Recce Pharmaceuticals's annualizedNet Income for the quarter that ended in Dec. 2022 was A$-18.45 Mil. Recce Pharmaceuticals's average total tangible assets for the quarter that ended in Dec. 2022 was A$7.63 Mil. Therefore, Recce Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2022 was -241.72%.
The historical rank and industry rank for Recce Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
ASX:RCE'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -269.99 Med: -128.33 Max: -64.05
Current: -142.64
During the past 7 years, Recce Pharmaceuticals's highest Return-on-Tangible-Asset was -64.05%. The lowest was -269.99%. And the median was -128.33%.
ASX:RCE's Return-on-Tangible-Asset is ranked worse than 88.76% of 1575
companies
in the Biotechnology industry
Industry Median: -38.11
vs ASX:RCE: -142.64
Recce Pharmaceuticals Return-on-Tangible-Asset Historical Data
The historical data trend for Recce Pharmaceuticals's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Recce Pharmaceuticals Annual Data
Trend
Jun16
Jun17
Jun18
Jun19
Jun20
Jun21
Jun22
Return-on-Tangible-Asset
-128.33
-269.99
-207.25
-108.42
-64.05
Recce Pharmaceuticals Semi-Annual Data
Jun16
Dec16
Jun17
Dec17
Jun18
Dec18
Jun19
Dec19
Jun20
Dec20
Jun21
Dec21
Jun22
Dec22
Return-on-Tangible-Asset
-145.74
-28.62
-51.86
-81.72
-241.72
Competitive Comparison
For the Biotechnology subindustry, Recce Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recce Pharmaceuticals Return-on-Tangible-Asset Distribution
For the Biotechnology industry and Healthcare sector, Recce Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Recce Pharmaceuticals's Return-on-Tangible-Asset falls in comparison to its industry or sector. The grey bar indicates the Return-on-Tangible-Asset's extreme value range as defined by GuruFocus.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2022) net income data.
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Recce Pharmaceuticals Return-on-Tangible-Asset Related Terms
Thank you for viewing the detailed overview of Recce Pharmaceuticals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Recce Pharmaceuticals (ASX:RCE) Business Description
Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. It operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat the diseases caused by various bacterias namely Sepsis, Helicobacter Pylori, Escherichia coli, Pseudomonas aeruginosa, and others.
Create New Portfolio
Portfolio Contest
Personalize
Premium Gurus 
(2.56%) Volume: 103,369 Mar. 29
Email Alerts
Stock PDF
RSS
Website
Sources
Download
Manual of Stocks™ Web APP
ASX:RCE has been successfully added to your 
